
|Videos|April 9, 2021
Visus presbyopia drop gets FDA IND OK
A presbyopia-correcting eyedrop recently received FDA acceptance of its investigational new drug (IND) application
Advertisement
Rhett Schiffman, MD, MHSA, chief medical officer and head of research and development at Visus Therapeutics, talks with Gretchyn Bailey, NCLC, FAAO, editor in chief of Optometry Times® about Brimichol, the company’s presbyopia-correcting eyedrop that recently received FDA acceptance of its investigational new drug (IND) application.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Spotlight on human trafficking: A virtual epidemic in the US
2
Crafting your own eyewear brand: An introduction to Logoproject Eyewear
3
How to put wearable virtual reality technology to work in your practice
4
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
5















































.png)


